medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2016; 15 (4)


Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C

Forns X, Samuel D, Mutimer D, Fagiuoli S, Navasa M, Agarwal K, Berenguer M, Colombo M, Herzer K, Nevens F, Daems B, Janssen K, Ouwerkerk-Mahadevan S, Kimko H, Lathouwers E, Witek J, Solingen-Ristea RV

Idioma: Ingles.
Referencias bibliográficas: 40
Paginas: 512-523
Archivo PDF: 348.91 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. European Association for the Study of the Liver. The burden of liver disease in Europe. Available from: http:// w w w . e a s l . e u / m e d i a s / E A S L i m g / D i s c o v e r / E U / 54ae845caec619f_file.pdf [accessed 18.09.15].

  2. Teixeira R, Pastacrolimusaldi S, Papateodoridis GV, Burroughs AK. Recurrent hepatitis C after liver transplantation. J Med Virol 2000; 61: 443-54.

  3. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-7.

  4. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, Córdoba J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-84.

  5. Berenguer M. Hepatitis C after liver transplantation: risk factors, outcomes, and treatment. Curr Opin Organ Transplant 2005; 10: 81-9.

  6. Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373-83.

  7. Braks RE, Ganne-Carrié N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, Pol S, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007; 13: 5648-53.

  8. Carrion J, Navasa M, Garcia-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, Bosch J, et al. Efficacy of antiviral therapy on HCV recurrence after liver transplantation: A randomised-controlled study. Gastroenterology 2007; 132: 1746-56.

  9. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.

  10. Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol 2012; 26: 205-10.

  11. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon- based Combination anti-Viral therapy for Hepatitis C Virus after liver transplantation: A review and quantitative analysis. Am J Transplant 2006; 6: 1586-99.

  12. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New Engl J Med 2011; 364: 2405-16.

  13. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. New Engl J Med 2011; 365: 1014-24.

  14. INCIVO (telaprevir) EU Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Product_Information/human/ 002313/WC500115529.pdf [accessed 18.09.2015].

  15. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.

  16. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.

  17. VICTRELIS (boceprevir) EU Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/human/ 002332/WC500109786.pdf [accessed 18.09.2015].

  18. OLYSIO (simeprevir) EU Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/human/ 002777/WC500167867.pdf [accessed 18.09.2015].

  19. SOVALDI (sofosbuvir) EU Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/human/ 002798/WC500160597.pdf [accessed 18.09.2015].

  20. DAKLINZA (daclatasvir) EU Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/human/ 003768/WC500172848.pdf [accessed 18.09.2015].

  21. HARVONI (ledipasvir/sofosbuvir) EU Summary of Product Characteristics. Available from: http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR_-_Product_Information/ human/003850/WC500177995.pdf [Accessed 18.09.2015].

  22. VIEKIRAX (partiaprevir/ritonavir/ombitasvir) EU Summary of Product Characteristics. Available from: http://ec.europa.eu/ health/documents/community-register/2015/20150115130406/ anx_130406_en.pdf [Accessed 18.09.2015].

  23. EXVIERA (dasabuvir) EU Summary of Product Characteristics. Available from: http://ec.europa.eu/health/documents/community- register/2015/20150115130446/anx_130446_en.pdf [accessed 18.09.2015].

  24. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet 1996; 30: 141-79.

  25. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 1997; 16: 267-78.

  26. Shiraga T. Oxidative metabolism of tacrolimus and its metabolite by human cytochrome P450 3A subfamily. Drug Metab Pharmacokinet 1999; 14: 277-85.

  27. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP, et al. Telaprevir-based triple therapy in liver transplant patients with Hepatitis C virus: A 12-Week pilot study providing safety and eficacy data. Liver Transpl 2012; 18: 1464-70.

  28. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP, et al. Feasibility of telaprevir-based triple therapy in liver transplant patients with Hepatitis C virus: SVR 24 results. PLOS One 2013; 8: e80528.

  29. Garg V, van Heeswik R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-7.

  30. Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW, Al-Judaibi B, et al. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Ann Hepatol 2014; 13: 525-32.

  31. Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, et al. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLOS One 2012; 7: e34372.

  32. Coilly A, Dumortier J, Botta-Fridlund D, Latournerie M, Leroy V, Pageaux GP, Agostini H, et al. Multicenter experience with boceprevir or telaprevir to treat Hepatitis C recurrence after liver transplantation: When present becomes past, what lessons for future? PLoS One 2015; 10: e0138091.

  33. Burton JR, O’Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with proteaseinhibitor triple therapy. J Hepatol 2014; 61: 508-14.

  34. Giusto M, Rodriguez M, Navarro L, Rubin A, Aguilera V, San- Juan F, Ortiz C, et al. Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin. Liver Transpl 2011; 17: 1318-27.

  35. Gordon FD, Kwo P, Vargas HE. Treatment of hepatitis C in liver transplant recipients. Liver Transpl 2009; 15: 126-35.

  36. Bzowej N, Nelson DR, Tarrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR, et al. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528-38.

  37. O’Riordan A, Dutt N, Cairns H, Rela M, O’Grady JG, Heaton N, Hendry BM, et al. Renal biopsy in liver transplant recipients. Nephrol Dial Transplant 2009; 24: 2276-82.

  38. Gutierrez JA, Carrion AF, Avalos D, O’Brien C, Martin P, Bhamidimarri KR, Peyton A. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl 2015; 21: 823-30.

  39. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 Phase 3 study. Presented at the 50th Annual Meeting of the European Association of the Liver. (International Liver Congress™ 2015). Vienna, Austria, April 22-26. Abstract L08.

  40. Manns M, Forns X, Samuel D, Denning J, Arterburn S, Brandt-Sarif T, Dvory-Sobol H, et al. Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Prelimi nary results of the prospective SOLAR 2 trial. Presented at the 50th Annual Meeting of the European Association of the Liver. (International Liver Congress™ 2015). Vienna, Austria, April 22-26. Abstract G02.




2020     |     www.medigraphic.com